Growth Metrics

Karyopharm Therapeutics (KPTI) Gains from Investment Securities (2016 - 2025)

Karyopharm Therapeutics' Gains from Investment Securities history spans 14 years, with the latest figure at $39626.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 90.69% year-over-year to $39626.0; the TTM value through Dec 2025 reached $39626.0, down 90.69%, while the annual FY2025 figure was $39626.0, 90.69% down from the prior year.
  • Gains from Investment Securities reached $39626.0 in Q4 2025 per KPTI's latest filing, down from $425479.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $425479.0 in Q4 2024 to a low of -$231000.0 in Q2 2021.
  • Average Gains from Investment Securities over 5 years is $47592.1, with a median of $2000.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: crashed 300.0% in 2023, then skyrocketed 14082.63% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $177000.0 in 2021, then tumbled by 101.69% to -$3000.0 in 2022, then skyrocketed by 200.0% to $3000.0 in 2023, then surged by 14082.63% to $425479.0 in 2024, then crashed by 90.69% to $39626.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Gains from Investment Securities are $39626.0 (Q4 2025), $425479.0 (Q4 2024), and $3000.0 (Q4 2023).